Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

55.56USD
17 Nov 2017
Change (% chg)

$0.02 (+0.04%)
Prev Close
$55.54
Open
$55.29
Day's High
$55.71
Day's Low
$55.22
Volume
2,508,763
Avg. Vol
1,539,764
52-wk High
$56.68
52-wk Low
$37.38

Chart for

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.55
Market Cap(Mil.): $96,707.77
Shares Outstanding(Mil.): 1,740.60
Dividend: 0.26
Yield (%): 1.91

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-Abbott's mitraclip approved as first transcatheter mitral valve repair device in Japan

* Abbott's mitraclip approved as first transcatheter mitral valve repair device in Japan Source text for Eikon: Further company coverage:

Nov 06 2017

Fitch Withdraws Abbott Laboratories' Ratings

(The following statement was released by the rating agency) CHICAGO, November 02 (Fitch) Fitch Ratings has chosen to withdraw the ratings of Abbott Laboratories and St. Jude Medical, Inc. for commercial reasons. RATING SENSITIVITIES Ratings sensitivities are no longer relevant given today's withdrawal. FULL LIST OF RATING ACTIONS Fitch has affirmed and subsequently withdrawn the following ratings. Abbott Laboratories --Long-Term Issuer Default Rating 'BBB', Outlook Stable; --Senior unsecured ban

Nov 02 2017

BRIEF-Abbott gets FDA clearance for its Alinity ci-series instruments

* Abbott announces FDA clearance for its Alinity ci-series next-generation diagnostic systems

Oct 31 2017

BRIEF-Abbott says ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​

* Abbott - ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​ Source text for Eikon: Further company coverage:

Oct 23 2017

BRIEF-Abbott CFO says Alere is expected to contribute around $475 mln to reported sales this year

* Abbott CFO says Alere, is expected to contribute around $475 million to reported sales, and forecast a neutral impact on adjusted earnings per share this year - Conf Call

Oct 18 2017

Abbott's recent deals, medical device pipeline to fuel growth

Abbott Laboratories' quarterly results beat estimates and the company raised the top end of its full-year earnings forecast range on Wednesday, as a string of recent deals and medical device approvals help spur growth in its largest unit.

Oct 18 2017

UPDATE 3-Abbott's recent deals, medical device pipeline to fuel growth

* Shares up 2.8 pct to record high (Adds conference call details, updates shares)

Oct 18 2017

BRIEF-Abbott Q3 adjusted EPS $0.66 from continuing operations

* Sees FY 2017 gaap earnings per share $0.97 to $0.99 from continuing operations

Oct 18 2017

Abbott Labs posts quarterly profit vs. year-ago loss

Oct 18 Diversified healthcare company Abbott Laboratories on Wednesday reported a quarterly profit compared with a loss in the year-ago quarter, helped by strong sales in its medical devices and generics businesses.

Oct 18 2017

AbbVie, Abbott duck Depakote off-label marketing case on appeal

A federal appeals court on Thursday upheld the dismissal of a class action lawsuit accusing AbbVie Inc and Abbott Laboratories of violating federal racketeering laws by promoting the drug Depakote for off-label uses.

Oct 12 2017

Competitors

Earnings vs. Estimates